The role for neoadjuvant systemic therapy in resectable pancreas adenocarcinoma remains undefined. Objective: We evaluated the efficacy of gemcitabine and oxaliplatin administered as preoperative therapy in patients with resectable pancreas adenocarcinoma. Methods: Eligible patients were screened using computed tomographypancreas angiography, laparoscopy, endoscopic ultrasonography, and fineneedle aspiration cytology to identify 38 patients who received 4 cycles of neoadjuvant gemcitabine 1000 mg/m 2 intravenously over 100 minutes and oxaliplatin 80 mg/m 2 intravenously over 2 hours, every 2 weeks. Patients whose tumors remained resectable at restaging proceeded to operation and subsequently received 5 cycles of adjuvant gemcitabine (1000 mg/m 2 intravenously over 30 minutes days 1, 8, and 15 every 4 weeks). The primary endpoint was 18month overall survival and secondary endpoints included radiological, tumor marker and pathological response to neoadjuvant therapy, time to recurrence, patterns of failure, and feasibility of obtaining preoperative core biopsies. Results: Thirty-five of 38 patients (92%) completed neoadjuvant therapy. Twenty-seven patients underwent tumor resection (resectability rate 71%), of which 26 initiated adjuvant therapy for a total of 23 patients (60.5%) who completed all planned therapy. The 18-month survival was 63% (24 patients alive). The median overall survival for all 38 patients was 27.2 months (95% confidence interval: 17-NA) and the median disease-specific survival was 30.6 months (95% confidence interval: 19-NA). Conclusions: This study met its endpoint and provided a signal suggesting that exploration of neoadjuvant systemic therapy is worthy of further investigation in resectable pancreas adenocarcinoma. Improved patient selection and more active systemic regimens are key. Clinical trials identification: NCT00536874.
P ancreatic adenocarcinoma is characterized by having a 5-year survival rate of less than 6%, 1 due to late clinical manifestation and the systemic nature of the disease at presentation. Estimated 5-year survival rates after resection are between 15% and 20%. 2 Resection alone is inadequate for cure, and, traditionally, systemic therapy and/or combined chemotherapy and radiation have been added to surgical treatment. 3 These latter modalities are typically administered in the postoperative adjuvant setting. Multiple studies have shown that adjuvant therapy improves overall survival (OS), [4] [5] [6] but up to 25% of patients cannot receive this treatment because of surgical morbidity. 7, 8 Moreover, recent data suggest that in certain settings, less than half of patients with resected pancreatic cancer receive any form of adjuvant therapy. 9 Neoadjuvant treatment offers several theoretical advantages over an initial resection and adjuvant therapy paradigm, including early delivery of systemic therapy for all patients, a higher negative margin resection rate (when radiation is included), and enhanced patient selection for surgery, collectively leading to potentially improved survival. [10] [11] [12] Conversely, neoadjuvant treatment carries the risk of disease progression during therapy because of unfavorable tumor biology and/or an ineffective treatment. 10 A review of select trials for patients with localized pancreas cancer has suggested a benefit to neoadjuvant therapy by showing an increased median survival time 12, 13 and potentially higher resectability rates 14, 15 with neoadjuvant treatment.
However, neoadjuvant regimens for patients with resectable pancreatic cancer have been investigated in a few limited studies and have mostly examined combined chemoradiotherapy with/without systemic therapy and not systemic therapy alone. [16] [17] [18] A single small phase II prospective trial evaluating neoadjuvant gemcitabine and cisplatin for resectable adenocarcinoma of pancreatic head origin demonstrated feasibility, tolerability, and favorable overall and disease-free survival. 19 Another neoadjuvant prospective phase II trial demonstrated significant metabolic and histological tumor response with a neoadjuvant gemcitabine and cisplatin regimen and feasibility of surgery after this treatment. 20 The phase II trial reported herein explores the efficacy of neoadjuvant therapy with gemcitabine and oxaliplatin in patients with radiographically resectable pancreatic adenocarcinoma. The rationale for this systemic regimen was based in part on a phase III trial that compared gemcitabine and oxaliplatin therapy with gemcitabine in treatment of advanced pancreatic cancer. 21 This study reported that the combination was significantly superior to gemcitabine alone in terms of tumor response (26.8% vs 17.3%; P = 0.04), progressionfree survival (5.8 vs 3.7 months; P = 0.04), and clinical benefit (38.2% vs 26.9%; P = 0.03) and had a nonstatistically significant trend to benefit in median OS (9.0 vs 7.1 months; P = 0.13). 21 In addition, pooled and meta-analytical data of combination platinum-based therapies in metastatic pancreatic cancer report improved outcomes compared with gemcitabine alone in patients with good functional status. 7 Thus, we undertook an investigator-initiated, single-arm, nonrandomized phase II study of gemcitabine and oxaliplatin in patients with radiographically resectable pancreas adenocarcinoma.
PATIENTS AND METHODS

Patient Population
Patients aged 18 years and older with radiographically resectable pancreas cancer at Memorial Sloan-Kettering Cancer Center (MSKCC) were eligible. Pathological confirmation of diagnosis by aspiration or biopsy was necessary before initiation of treatment but not mandated at the time of enrollment. Radiographically resectable disease was defined as the following: no distant metastases; a clear fat plane around celiac and superior mesenteric arteries and a patent superior mesenteric vein and portal vein without primary tumor involvement; no encasement of the superior mesenteric vein or portal vein involvement; no encasement of the superior mesenteric artery or hepatic artery; and no extraregional nodal disease. All patients were discussed at a multidisciplinary conference, with final eligibility adjudication determined by surgical investigators (P.J.A., W.R.J.), medical oncology (E.M.O'R.), and study radiologist (C.W.). Additional key inclusion criteria were ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 to 1, measurable disease by RECIST (Response Evaluation Criteria in Solid Tumors, version 1.0); no major organ dysfunction; absolute neutrophil count of 1500 or more cells per mm 3 ; platelet count of 100,000 or more cells per mm 3 ; bilirubin levels of 4.0 or less before initiation of therapy; serum creatinine levels of 1.6 mg/dL or less; international normalized ratio of less than 1.5, unless on therapeutic anticoagulation; and no history of chemotherapy or radiation for pancreas cancer. Women of childbearing potential had to have a negative pregnancy test, and men and women of childbearing potential had to be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
Patients with histopathology other than adenocarcinoma and patients with borderline resectable or locally advanced pancreas adenocarcinoma were ineligible. Other exclusion criteria included a history of prior noncutaneous malignancy within 3 years of entry; history of hypersensitivity to chemotherapy agents or hypersensitivity to computed tomographic (CT) intravenous contrast dye, not suitable for premedication; presence of active infection except resolving cholangitis; and presence of peripheral neuropathy of grade 2 or more.
Trial Design and Treatment
The study design was of a single-institution, open-label, nonrandomized phase II trial of neoadjuvant therapy with gemcitabine and oxaliplatin in patients with radiographically resectable pancreatic adenocarcinoma. The primary endpoint was 18-month OS. Secondary endpoints included RECIST response to neoadjuvant therapy, tumor marker response and safety of neoadjuvant therapy, recurrence-free survival, failure patterns (first and all), disease-specific survival, and OS. Exploratory correlative endpoints included assessment of pathological response to neoadjuvant therapy and feasibility of obtaining endoscopic or laparoscopic core needle biopsy specimens.
Potentially eligible patients were staged with a pancreas protocol CT including chest and pelvis at MSKCC, followed by a staging laparoscopy to evaluate for subradiological distant metastasis and to obtain laparoscopic core biopsy specimens of the pancreas when feasible, for diagnostic and research purposes. Endoscopic ultrasonography (EUS) and fine-needle aspiration cytology were performed when not previously obtained. Endoscopic retrograde cholangiopancreatography was performed as clinically indicated for the placement of a biliary stent (metal recommended) for palliation of obstructive jaundice. Neoadjuvant protocol therapy involved 4 cycles of gemcitabine dosed at 1000 mg/m 2 intravenously over 100 minutes and oxaliplatin 80 mg/m 2 intravenously over 2 hours, with both drugs cycled every 2 weeks for 4 cycles. Oxaliplatin was supplied by Sanofi-Aventis.
After completion of neoadjuvant chemotherapy, all patients underwent a restaging pancreas protocol CT at MSKCC. All patients eligible for pancreatic resection proceeded to surgery at MSKCC that was to be performed at 2 weeks or later but no later than 6 weeks after the completion of neoadjuvant chemotherapy. A staging laparoscopy was conducted at the same operative procedure of definitive resection to reconfirm the absence of distant metastatic disease. Patients in whom distant metastasis was identified, or who were deemed to have locally advanced disease, were taken off the study, and further treatment was as recommended by the treating physicians. All patients who underwent either an R0/R1 surgical resection received 5 cycles of adjuvant gemcitabine (1000 mg/m 2 on days 1, 8, and 15, every 4 weeks) for 15 doses. Adjuvant chemoradiotherapy was not planned in this trial; however, it was selectively considered for patients who had an R1 resection. After completion of therapy, all patients were followed every 4 months for years 1 and 2, then every 6 months for years 3 to 5, and annually thereafter with tumor markers and CT of chest/abdomen/pelvis with oral and intravenous contrast or magnetic resonance imaging of the abdomen and noncontrast CT of the chest.
All patients provided written informed consent before enrollment. The MSKCC institutional review and privacy board reviewed this study. Clinical trials identification: NCT00536874.
Biostatistical Plan
The primary study endpoint was 18-month OS. The historical 18-month survival of patients who underwent laparoscopy and a pancreas protocol CT at MSKCC between 1998 and 2003 before resection was 53%. Enrollment of 37 patients would allow differentiation of an 18-month OS of 53% and 73%, with type I and II error rates of 10% each using a single-stage binomial design. The regimen was to be considered active if 24 or more patients were alive at 18 months. Patients were eligible for analysis of the primary endpoint if they received any dose of protocol-specified therapy, even if unable to complete neoadjuvant therapy or subsequent surgery. Secondary endpoints included RECIST (version 1.0) response and tumor marker response to neoadjuvant therapy, recurrence-free survival after surgery, failure patterns (first and all), safety [NCI CTCAE v3 (National Cancer Institute Common Terminology Criteria for Adverse Events, version 3)], and OS. OS was defined as time from signing protocol consent to death and was estimated using the Kaplan-Meier methodology, and the Greenwood formula was used to calculate the standard error of the Kaplan-Meier estimate and 95% confidence interval. For patients who underwent resection, recurrence-free survival was defined as the time from surgical resection to the time of first recurrence, local, distant, or both, or death, whichever occurred first. Recurrence was defined as when definitive evidence of recurrence was present, that is, mass and or biopsy confirmation and not on the basis of elevation of CA 19-9 (cancer antigen 19-9) levels in isolation. Disease-specific survival was defined as the time of signing protocol consent to death, with patients censored if they died of another cause. The contribution of surgery to outcome was evaluated by comparing OS between the resected and unresected patients, using the date of determination of nonresectability for the unresected patients as the reference date and by excluding patients who died early and thus were ineligible for resection.
Correlative objectives included feasibility of obtaining preoperative core tissue samples by either laparoscopic or EUS-based approaches. Feasibility was achieved if 60% or more of patients had core samples obtained and if 75% or more of samples were adequate for assessment. Pathological response to treatment was determined on the basis of the amount of residual viable carcinoma in relation to areas of fibrosis and fibroinflammation in the gross lesion. 22 A 100% treatment response represented either fibrosis or fibroinflammation within an entire gross lesion without microscopic evidence of carcinoma; a 0% response represented an entirely viable tumor in the absence of fibrosis/fibroinflammation.
RESULTS
This trial enrolled 49 patients from July 2007 to December 2011. Eleven were excluded: 6 had metastases at staging laparoscopy; 2 had autoimmune pancreatitis; 1 patient withdrew consent; and for 2 patients, a diagnosis of malignancy could not be confirmed. Thirtyeight patients received protocol-specified therapy. The median age was 73 years, 23 (61%) were men, 24 (63%) had an ECOG PS of 1, and 31 (81.5%) had the primary tumor located in the head of the pancreas. Patient flow for the study is illustrated in Figure 1 , and demographic information is summarized in Table 1 . The data analysis cutoff point was December 31, 2012.
Neoadjuvant Therapy, Safety, and Radiological Response
Of 38 patients who initiated neoadjuvant therapy, 35 (92%) completed all 4 cycles of treatment. Preoperative therapy was mostly well tolerated ( Table 2 ). One patient (2.6%) experienced a grade 3 hypersensitivity reaction to oxaliplatin with the second dose and was not rechallenged with oxaliplatin. There were 3 unexpected fatali- ties during preoperative therapy (7.9%). Two patients with a history of underlying heart disease had grade 5 cardiac events, myocardial infarction, and a fatal arrhythmia. Both were deemed unrelated to therapy. One additional patient had a cerebrovascular accident after the second dose of therapy and was removed from the study and died shortly thereafter. One patient experienced a grade 3 hemorrhage The values given are number (percentages). * Electrolyte abnormalities, including hyper-/hyponatremia, hyper-/hypokalemia, hyper-/hypomagnesemia, and hyper-/hypophosphatemia. †Patient had hemorrhage from the primary tumor site related to erosion into the duodenum after the second cycle of therapy and proceeded to surgery thereafter. ‡Infusion/hypersensitivity reaction to oxaliplatin after the second dose; no further oxaliplatin was administered. Neoadjuvant therapy was completed with gemcitabine alone.
§Fatal myocardial infarction (n = 1); fatal arrhythmia (n = 1). ALT indicates alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; PT/PTT/INR, prothrombin time/partial thromboplastin time/international normalized ratio. from the primary tumor site due to erosion into the duodenum after the second cycle of therapy and proceeded to surgery early.
Response to Preoperative Therapy: Radiological and Tumor Marker
A low objective radiological response rate was observed with 4 (10.5%) partial responses, and the majority of patients having stable disease (28; 73.7%). Three patients (7.9%) had progression of disease. Minor changes in CEA (carcinoembryonic antigen) and CA 19-9 were observed. Data are summarized in Table 3 .
Surgical and Pathological Outcomes
After preoperative therapy, 35 patients were surgical candidates and proceeded to operation, of whom 27 (77%) underwent an R0/R1 resection. Eight of 35 patients (23%) were found to have unresectable disease at the time of operation (3 metastases; 5 locally unresectable). Twenty-six patients (96%) had adenocarcinoma. The median resected tumor size was 2.8 cm; 9 patients (33.5%) had negative lymph nodes, and 20 (74%) underwent an R0 resection. The majority (18; 66.5%) had AJCC (American Joint Committee on Cancer) stage IIB disease. These data are summarized in 
Adjuvant Therapy
Of 27 patients who underwent tumor resection, 26 (96%) proceeded to adjuvant therapy. One patient with adenosquamous cancer had new liver metastases on the baseline postoperative CT scan. Twenty-three patients (60.5%) completed all protocol-specified therapy. Three patients (11%) developed metastatic disease during adjuvant therapy. Adjuvant therapy was generally well tolerated with no unexpected toxicity. Three patients (11%) received adjuvant chemoradiation after protocol therapy in view of an R1 resection. Data are summarized in Supplemental Digital Content Table 2s (available at http://links.lww.com/SLA/A475).
Survival, Recurrence Outcomes, and Patterns of Failure
The median follow-up time was 39.6 months (range, 12.3-57.7 months). For the primary study endpoint of 18-month OS, 24 patients were alive [Kaplan-Meier estimate of 63% with 95% confidence interval (CI): 45-76]. One patient was completing therapy at 12 months from diagnosis. For all 38 patients, the median OS was 27.2 months (95% CI: 17-NA) (Fig. 2) . The median diseasespecific survival was 30.6 months (95% CI: 19-NA) with 4 patients censored (Supplemental Digital Content Figure 2s , available at http://links.lww.com/SLA/A477). For the 27 patients who underwent surgery, the median recurrence-free survival after surgery was 22 months (95% CI: 11-27) (see Supplemental Digital Content Figure  1s , available at http://links.lww.com/SLA/A476). Of the 27 resected patients, 5 were alive without recurrence, 19 had disease recurrence with metastases as the first site of recurrence (liver 7, peritoneum 6, nodes 3, lung 3), 1 patient had recurrence at both local and systemic sites concurrently, and 1 patient had a lung-only site of first failure. One patient developed a second pancreas primary (T3, N0) and underwent a completion pancreatectomy and remained free of recurrence from both pancreas primaries. One patient died of unrelated causes after hip surgery complications.
Of 11 unresected patients, 3 experienced early death and 8 died of pancreatic cancer with an OS range of 5 to 32 months. Two of these 8 patients, who experienced local progression during preoperative therapy, subsequently received chemoradiation and underwent surgery; both had recurrence and died at 13 and 20 months after surgery. Patients who underwent resection had a significantly improved OS compared with those that did not (P = 3 (37.5) * n = 1 had incidentally detected primary mucinous well-differentiated ovarian neoplasm resected at the time of Whipple surgery; n = 1 patient had the incidental neuroendocrine cancer resected concurrent with distal pancreatectomy. †n = 2 superior mesenteric artery involvement; n = 2 superior mesenteric vein-portal venous confluence invasion.
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Correlative Endpoints
A key exploratory endpoint was to evaluate the feasibility of obtaining preoperative core tissue samples on either laparoscopy or EUS for the purpose of xenograft implantation and comparison of preoperative with postoperative specimens with regard to pathological tumor response. Five preoperative cores were obtained, all from body/tail primary tumors by either laparoscopic biopsy (n = 3) or endoscopic biopsy (n = 2). Xenograft implantation was successful in 1 sample. Feasibility was not demonstrated. Operative specimens of 27 patients were banked for future study.
In view of the inability to obtain pretreatment core biopsy specimens in the majority of patients, pathological response was determined by evaluation of the operative specimen. Modest pathological treatment effect was evident ( Table 4 ). Pre-and postneoadjuvant sera were obtained from all patients for multianalyte protein expression profiling and will be reported separately.
adenocarcinoma. [26] [27] [28] There are many limitations in the published literature pertaining to neoadjuvant therapy. First, most are singleinstitution experiences and very few studies report data for resectable pancreas cancer with systemic therapy alone. Second, many studies have not clearly defined the patient population under study, and, third, the relative contribution of systemic therapy versus chemoradiation versus both modalities has not been defined. Selected singleinstitution experiences, for example, a 2008 MD Anderson phase II study, 29 have shown that preoperative combined chemoradiotherapy using gemcitabine was associated with favorable survival duration for patients who were able to complete all planned therapy; it remains unclear whether this reflects treatment impact or patient selection. Data from a recent, large, pooled, and meta-analytical review in 2010 does not suggest a significant advantage of neoadjuvant therapy with respect to resectability and survival rates when compared with upfront surgical resection and adjuvant therapy in treatment of resectable pancreatic cancer; however, improved survival was associated with preoperative therapy for patients initially regarded as locally advanced and/or unresectable. 26 Our phase II trial explored the efficacy of neoadjuvant therapy with gemcitabine and oxaliplatin in patients with resectable pancreatic adenocarcinoma. Our study met its primary endpoint and provided a signal with a median OS of 27.2 months in the face of a median age of study participants of 73 years in contrast to usual pancreas trials typically reporting a median age in the low 60s. With respect to secondary endpoints, there was a low RECIST, tumor marker, and pathological response to gemcitabine and oxaliplatin. These observations are explained by the relatively modest cytotoxic activity of gemcitabine and oxaliplatin. Arguably more active combinations such as FOLFIRINOX 30 or gemcitabine and albumin-bound paclitaxel 31 may increase the number of objective responses to preoperative therapy. Nonetheless, response evaluation can be challenging and, in part, the visible mass may contain components of inflammation and desmoplastic stroma and RECIST criteria may over-/underestimate response. 32 A correlative objective was to obtain sufficient pretherapy tissue at either EUS evaluation or laparoscopy for the creation of human xenografts and for comparison with the resected specimen. This proved to be particularly challenging, with success obtained in a limited number of patients and only in those with body or tail tumors with the retrieval of very small core biopsy specimens. Recent advances in endoscopic tools may permit larger microcore biopsy specimens to be obtained from head tumors, which will hopefully offer enhanced opportunities for obtaining pretreatment tissue in sufficient quantity to permit more than just diagnostic evaluation.
A prospective randomized controlled trial is the most effective way to compare the benefits of a neoadjuvant strategy with upfront surgery followed by adjuvant approach, recognizing that there are many challenges to undertaking such a trial. 23 It is also plausible that some of the observed outcome improvement in this study, over reported outcomes from recent adjuvant phase III trials results (ESPAC-3, CONKO-001, RTOG 97-04, JASPAC-01) 4,33-35 reflects high-quality multidisciplinary care. Learning points from the study were the requirement of timely collaboration to facilitate expeditious diagnostic workup with the goal of having patients commence neoadjuvant therapy within 2 to 3 weeks of their entry point to the system along with improved patient selection.
CONCLUSIONS
Our phase II trial demonstrated that neoadjuvant gemcitabine and oxaliplatin therapy was active and provided an interesting survival signal. Institutionally, we are committed to develop further neoadjuvant therapy as a research direction in resectable pancreas cancer building on the observations from this trial in the context of more active regimens.
